D. Boral Capital Reaffirms Buy Rating for Enlivex Therapeutics (NASDAQ:ENLV)

Posted by Donald Scott on Feb 7th, 2025

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $13.00 price target on the stock.

Enlivex Therapeutics Trading Down 6.4 %

ENLV opened at $1.03 on Friday. Enlivex Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.59. The company has a market cap of $22.05 million, a P/E ratio of -1.05 and a beta of 0.99. The company’s 50 day moving average is $1.18 and its 200-day moving average is $1.29.

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last posted its quarterly earnings data on Friday, November 29th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. On average, equities analysts forecast that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. acquired a new stake in Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned 0.14% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.